Liminatus Pharma, Inc. SEC filings LIMNW
Liminatus Pharma, Inc. has 109 filings in SEC EDGAR's recent list, going back to May 2, 2023. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (material agreement, unregistered share sale). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Jun 18, 2026 | — |
| EFFECT | Filing | Feb 13, 2026 | — |
| CORRESP | Letter to the SEC | Feb 11, 2026 | — |
| CORRESP | Letter to the SEC | Feb 11, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2026 | — |
| DRS | Filing | Dec 31, 2025 | — |
| NT 10-Q | Filing | Aug 15, 2025 | Jun 30, 2025 |
| EFFECT | Filing | Aug 12, 2025 | — |
| CORRESP | Letter to the SEC | Aug 11, 2025 | — |
| CORRESP | Letter to the SEC | Jul 25, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2025 | — |
| NT 10-Q | Filing | May 15, 2025 | Mar 31, 2025 |
| 8-K12B | Filing | Apr 30, 2025 | Apr 30, 2025 |
| EFFECT | Filing | Feb 6, 2025 | — |
| CORRESP | Letter to the SEC | Feb 4, 2025 | — |
| CORRESP | Letter to the SEC | Jan 27, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2025 | — |
| CORRESP | Letter to the SEC | Jan 15, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2024 | — |
| EFFECT | Filing | Aug 9, 2024 | — |
| CORRESP | Letter to the SEC | Aug 9, 2024 | — |
| CORRESP | Letter to the SEC | Aug 8, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2024 | — |
| CORRESP | Letter to the SEC | Aug 7, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 5, 2024 | — |
| CORRESP | Letter to the SEC | Jul 25, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2024 | — |
| CORRESP | Letter to the SEC | Jun 14, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2023 | — |
| CORRESP | Letter to the SEC | Nov 8, 2023 | — |
| UPLOAD | Letter from the SEC | May 30, 2023 | — |
| DRS | Filing | May 2, 2023 | — |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LIMN (Nasdaq), LIMNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cerritos, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1971387
- Former names
- Iris Parent Holding Corp. (until Feb 7, 2025)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.